Navigation Links
Regeneron Announces June 2012 Investor Conference Presentations
Date:5/30/2012

TARRYTOWN, N.Y., May 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Goldman Sachs Global Healthcare Conference 2012 at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time) on Tuesday, June 5, 2012
  • Jefferies 2012 Global Healthcare Conference at 10:30 a.m. Eastern Time on Thursday, June 7, 2012

    • The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  Archived versions of the presentations will be available for thirty days after the live webcasts. 

    Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection for Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information: Mani
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2

    Related medicine technology :

    1. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
    2. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
    3. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
    4. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
    5. Regeneron Announces February 2012 Investor Conference Presentations
    6. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
    7. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
    8. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
    9. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
    10. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
    11. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... , May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... been named the 2013 Life Science Firm of the Year ... (TCM).  Vanda was honored at the TCM,s 25 th ... , Maryland.  The Tech Awards Celebration recognizes the leaders and ... Maryland and the surrounding regions. ...
    (Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
    (Date:5/23/2013)...  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), ... on intellectual property developed and owned by Hadassah ... medical research center, today announced that its portfolio ... from the Israeli Ministry of Industry and Commerce, ... product development and advance clinical trials. Cell Cure,s ...
    Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
    ... DETROIT , March 11 Caraco ... launched oxaliplatin injections. These 50mg and 100mg oxaliplatin injections, ... approval from the US Food and Drug Administration (FDA) ... is an anticancer used in the treatment of colon ...
    ... today the commercial launch of its new VivoTag ® 680 XL fluorescent dye for labeling biomolecules in a broad range of ... ... ... ...
    Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R) 2Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Eloxatin(R) 3VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label 2VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label 3VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label 4
    (Date:5/24/2013)... Wednesday, 15th May 2013 | 10am BST | 5pm ... playback: http://bit.ly/10Rt0ZH , Ongoing regulatory changes are likely ... globe and particularly in Europe, a number of these new ... For dealmakers, understanding how the likes of Basel iii, Solvency ... corner of the market will give you a competitive edge ...
    (Date:5/24/2013)... 2013 HCG EZ Drops has been ... to announce it’s new weight loss initiative. “We are so confident ... our customers their money back if they don’t lose 21 pounds ... EZ Drops. “The HCG Diet consists of 21 days of ... in 21 days.” , The controversial, cutting-edge diet has been hailed ...
    (Date:5/24/2013)... (PRWEB) May 24, 2013 The leading retail ... discount offer on short prom dresses . Now that ... that is standard with the brand name since its origin. ... in prom dresses. And now this huge discount offer will ... “I feel highly privileged to announce that Short ...
    (Date:5/23/2013)... Los Angeles, CA (PRWEB) May 23, 2013 ... healthcare delivery has been gradually transforming, which has affected ... by medical school debt and seeking regular hours, more ... instead joining hospitals or other medical groups,” says IBISWorld ... operating costs and reimbursement pressure, a number of older ...
    (Date:5/23/2013)... PHILADELPHIA, May 24, 2013 -- High blood glucose is ... of intensive insulin therapy (IIT) to control hyperglycemia is ... does not show a consistent benefit and even shows ... the American College of Physicians, (ACP) Clinical Guidelines Committee ... the American Journal of Medical Quality . , ...
    Breaking Medicine News(10 mins):Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2
    ... readmitted within a year, study finds , , WEDNESDAY, April ... discharged from the hospital is readmitted within 30 days, ... a year, a new study finds. , The groundbreaking ... that researchers believe could be prevented through better care ...
    ... Calif., April 1, 2009 UC Irvine pharmacological researchers ... regulation can limit cocaine cravings. Their findings could herald ... Shinjae Chung and Olivier Civelli, the study identified how ... "pleasure center" to create an addictive response to cocaine ...
    ... NVAX) announced today that it has ... common stock at $0.88 per share to a wholly owned subsidiary ... Novavax and Cadila. Novavax intends to use the $11 million in ... 4.75% senior convertible notes due in July 2009 and for a ...
    ... April 1 Medicare beneficiaries who need physical ... efficient to obtain treatment under legislation introduced yesterday ... Patient Access to Physical Therapists Act (HR 1829), ... (R-PA), and Tammy Baldwin (D-WI), eliminates the need ...
    ... AILA believes this reform must include a rational model for giving American ... that can open the door to innovation and international markets. , ... ... fuel to speed it to recovery. And, once recovered, it ...
    ... April 1 On April 1st, Professional Healthcare Resources ... patients in their homes. The company was started in ... and has grown to an organization offering home health, ... of Columbia, and Virginia. The company has over 700 ...
    Cached Medicine News:Health News:High Rate of Rehospitalizations Costing Billions 2Health News:High Rate of Rehospitalizations Costing Billions 3Health News:UCI researchers find new way to fight cocaine addiction 2Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2Health News:Legislation Aims to Increase Access to Physical Therapist Services By Eliminating Physician Referral Requirement 2Health News:Legislation Aims to Increase Access to Physical Therapist Services By Eliminating Physician Referral Requirement 3Health News:AILA Believes There Has To Be a Better Way When It Comes to the H-1B Lottery 2Health News:AILA Believes There Has To Be a Better Way When It Comes to the H-1B Lottery 3Health News:Professional Healthcare Resources Celebrates 15 Year Anniversary 2
    ... is the first truely web-based solution on the ... POC (managed from the lab) and Critical Care ... of AegisPOC ensures that all groups have the ... in the manner best suited to them. Through ...
    ...
    ... The Vari-Lase Endovenous Laser System is ... for varicose veins in the leg. Endovenous ... surgical vein-stripping for the treatment of varicose ... laser fiber is inserted into the varicosed ...
    Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
    Medicine Products: